MSP

Pyro

1A





Additional Figure 1. Quantitative bisulfite pyrosequencing of MIR129-2. Pyrograms showing the methylation intensity on a stretch of 9 neighboring CpG dinucleotides of **(A)** Positive control with methylated DNA and normal control, and **(B)** Cell lines with defined MSP methylation statuese (MM, MU, and UU).

MSP

Pyro

1B

MINO

MSP: MM

Pyro: 84.67%



NCI-H929

MSP: MU

Pyro: 48.78%



RPMI-8226

MSP: UU

Pyro: 5.33%





Additional Figure 2. Expression of MIR129 in cell lines completely or partially methylated for MIR129-2. Box-and-whisker plot showed complete methylation of MIR129-2 was associated with a lower level of MIR129 expression, and hence a higher ΔCt (Ct MIR129 - Ct SNORD48) than partial methylation. The box indicated the 25th and 75th percentile and the whiskers represent the range, or the 25th percentile minus 1.5 X interquartile range when skewed datum (*) exists. The horizontal line indicated the median.

MSP

Pyro

3A

<u>Methylated sample S14</u>

MSP: MU

Pyro: 24.33%



<u>Methylated sample S15</u>

MSP: MU

Pyro: 33.67%



Additional Figure 3. Quantitative bisulfite pyrosequencing of MIR129-2. Pyrograms showing the methylation intensity on a stretch of 9 neighboring CpG dinucleotides of **(A)** methylated primary NHL samples, and **(B)** unmethylated primary NHL samples.

MSP

Pyro

3B

Unmethylated sample S12

MSP: UU

Pyro: 5.78%



Unmethylated sample S13

MSP: UU

Pyro: 5.78%



Additional Figure 3. Quantitative bisulfite pyrosequencing of MIR129-2. Pyrograms showing the methylation intensity on a stretch of 9 neighboring CpG dinucleotides of **(A)** methylated primary NHL samples, and **(B)** unmethylated primary NHL samples.



Additional Figure 4. Quantitative bisulfite pyrosequencing of MIR129-2. Pyrograms showing the methylation intensity on a stretch of 9 neighboring CpG dinucleotides of JEKO-1 cells before and after 5-azadC treatment.